Chemoradiotherapy Clinical Trial
Official title:
A Phase II Study for Short Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination With Capecitabine in Patients With Resectable Rectal Carcinoma
Intensity modulated radiotherapy (IMRT)-based radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Investigators initiated a prospective study to evaluate the efficacy and toxicity of short course preoperative chemoradiotherapy utilizing Intensity Modulated Radiation Therapy (IMRT) in combination with capecitabine in patients with resectable rectal carcinoma.
Preoperative chemoradiotherapy has become a standard part of treatment protocols in stage II
and III rectal cancer. Compared to postoperative chemoradiotherapy, the advantage of
preoperative application of chemotherapeutics and irradiation includes improved compliance,
reduced toxicity, and downstaging of the tumor in a substantial number of patients. The
latter may enhance the rate of curative surgery, permit sphincter preservation in patients
with low-sited tumors, and have a positive impact on the quality of life of these patients
(Sauer et al, 2004).
The most widely used chemotherapeutic agent in colorectal cancer has been 5-fluorouracil
(5-FU), and numerous attempts have been made to improve its efficacy, including
biomodulation and protracted infusion. It has been demonstrated that biomodulation with
leucovorin or levamisole was not effective in rectal cancer (Tepper et al, 2002), and
protracted infusion of 5-FU was superior to bolus injection (O'Connell et al, 1994). New
oral chemotherapeutic agents including capecitabine have been introduced and tried in
colorectal cancer. Capecitabine is a tumor-selective fluoropyrimidine carbamate designed to
achieve a higher intratumoral 5-FU level with lower systemic toxicity than intravenous
administration of 5-FU (Shimma et al, 2000). It passes intact through the intestinal mucosa
and is converted to 5-FU, preferentially in tumor tissue by thymidine phosphorylase
(Schuller et al, 2000 ; Ishikawa et al, 1998 ; Miwa et al, 1998). Theoretically, oral
capecitabine mimics the effect of protracted infusion of 5-FU without complications
accompanying intravenous delivery (Liu et al, 1997). Moreover, experimental data using human
cancer xenografts demonstrated up-regulation of thymidine phosphorylase by radiation (Sawada
et al, 1999), constituting a synergistic effect. In two randomized Phase III trials,
capecitabine showed a superior overall response rate and safety profile compared with
5-FU/lecovorinin for metastatic colorectal cancer (Van Cutsem et al, 2001; Hoff et al, 2001;
Twelves, 2002). Intensity modulated radiotherapy (IMRT)-based radiation therapy that
delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause
less damage to normal tissue. (Ballonoff et al, 2008)
With such encouraging outcomes, investigators initiated a prospective study to evaluate the
efficacy and toxicity of short course preoperative chemoradiotherapy utilizing Intensity
Modulated Radiation Therapy (IMRT) in combination with capecitabine in patients with
resectable rectal carcinoma.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
Recruiting |
NCT03286348 -
Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer
|
N/A | |
Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT04278287 -
Chemoradiotherapy in Unresectable Esophageal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05863260 -
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
|
||
Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
Completed |
NCT04207918 -
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT06219083 -
Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy
|
||
Active, not recruiting |
NCT04764227 -
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
|
Phase 2 | |
Recruiting |
NCT06421376 -
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05286086 -
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
|
N/A | |
Recruiting |
NCT04772001 -
Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer
|
N/A | |
Recruiting |
NCT06410651 -
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT06429839 -
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
|
Phase 2 | |
Recruiting |
NCT03177382 -
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
|
Phase 3 | |
Not yet recruiting |
NCT06413342 -
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05590650 -
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
|
Phase 1 | |
Recruiting |
NCT06190847 -
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
|